A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2

Cell Res. 2020 Oct;30(10):932-935. doi: 10.1038/s41422-020-0387-5. Epub 2020 Aug 5.

Authors

Affiliations

¹ Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, 10065, USA.
² Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
³ Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, 10065, USA. sjiang@nybc.org.
⁴ Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, 10065, USA. ldu@nybc.org.

^# Contributed equally.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antibodies, Neutralizing / immunology
Betacoronavirus / chemistry
Betacoronavirus / genetics*
Betacoronavirus / immunology
COVID-19
COVID-19 Vaccines
Cell Line
Coronavirus Infections / genetics
Coronavirus Infections / immunology
Coronavirus Infections / prevention & control*
Gene Expression
Humans
Immunization
Mice, Inbred BALB C
Pandemics / prevention & control*
Pneumonia, Viral / immunology
Pneumonia, Viral / prevention & control*
Protein Domains
RNA, Messenger / genetics
RNA, Messenger / pharmacology
RNA, Messenger / therapeutic use*
SARS-CoV-2
Spike Glycoprotein, Coronavirus / chemistry
Spike Glycoprotein, Coronavirus / genetics*
Spike Glycoprotein, Coronavirus / immunology
Viral Vaccines / genetics
Viral Vaccines / pharmacology
Viral Vaccines / therapeutic use*

Substances

Antibodies, Neutralizing
COVID-19 Vaccines
RNA, Messenger
Spike Glycoprotein, Coronavirus
Viral Vaccines
spike protein, SARS-CoV-2

Grants and funding